Expanding the Therapeutic Window in RAS-Driven Cancers: Targeted Degradation via DAC Technology to Enable Safe Pan-KRAS Targeting
- Enabling pan-KRAS/pan-RAS targeting with a potentially improved therapeutic window through antibody-guided DAC technology
- Delivering differentiated biology beyond inhibition by degrading RAS proteins and disrupting downstream signaling pathways
- Advancing toward clinical validation with a growing portfolio of RAS degraders and imminent clinical candidate progression